Double Arc Slow Cyclophotocoagulation: Effectiveness And Safety At 12 Months In Refractory Glaucoma

Published 2026 - 44th Congress of the ESCRS

Reference: POGAU076 | Type: Free paper | DOI: 10.82333/rqw9-9n22

Authors: Dr Luis Miguel Oviedo Plathi* ¹ , Dr Jean Morales ² , Dr Nelly Rosillo ³ , Dr Michelle Petitto ⁴ , Dr Jose Galue ⁵ , Dr Daniel Medina ⁶ , Dr Nelson Sanguinetty ⁷ , Dr Humberto Ramirez ⁸

¹Glaucoma,Hospital Universitario de Maracaibo,Maracaibo,Venezuela, Bolivarian Republic Of;Glaucoma,IDEO,Maracaibo,Venezuela, Bolivarian Republic Of;Glaucoma ,Clinica de Ojos,Maracaibo,Venezuela, Bolivarian Republic Of, ²Anterior Segment &amp; Cornea,Hospital Universitario de Maracaibo,Maracaibo ,Venezuela, Bolivarian Republic Of;Anterior Segment &amp; Cornea,IDEO,Maracaibo,Venezuela, Bolivarian Republic Of;Anterior Segment &amp; Cornea,Clinica de Ojos ,Maracaibo ,Venezuela, Bolivarian Republic Of, ³Glaucoma,IDEO,Maracaibo,Venezuela, Bolivarian Republic Of, ⁴Glaucoma,Clinica de Ojos,Maracaibo,Venezuela, Bolivarian Republic Of, ⁵Anterior Segment &amp; Cornea,Hospital Universitario de Maracaibo,Maracaibo,Venezuela, Bolivarian Republic Of;Anterior Segment &amp; Cornea,Clinica de Ojos,Maracaibo,Venezuela, Bolivarian Republic Of, ⁶Glaucoma,Hospital Universitario de Maracaibo,Maracaibo ,Venezuela, Bolivarian Republic Of;Glaucoma,IDEO,Maracaibo,Venezuela, Bolivarian Republic Of, ⁷Glaucoma,Hospital Universitario de Maracaibo,Maracaibo,Venezuela, Bolivarian Republic Of;Glaucoma,IDEO,Maracaibo,Venezuela, Bolivarian Republic Of, ⁸Glaucoma,Hospital Universitario de Maracaibo,Maracaibo,Venezuela, Bolivarian Republic Of

Purpose

To evaluate the effectiveness and Safety of double arc slow cook continuous-wave transscleral cyclophotocoagulation (DA-SC-CW-TSCPC) in refractory glaucoma.

Setting

University Hospital of Maracaibo, Maracaibo – Zulia.

Methods

Prospective observational study including 69 eyes with refractory glaucoma. IOP was recorded at baseline, 1 week, 1 month, 3 months, 6 months and 1 year. Pain was assessed using a visual analogue scale (VAS) at baseline, 3 months, 6 months and 1 year. Topical hypotensive medications were recorded at baseline and at 1, 3, 6 months and 1 year. Paired comparisons versus baseline used Wilcoxon tests. Complete success was defined as IOP 6–18 mmHg with ≥30% reduction without medication. Qualified success was defined as the same criteria allowing topical therapy but without oral acetazolamide.

Results

Mean age 61.1±17.8 years; 95.7% had severe disease. Mean IOP decreased from 42.25±16.37 mmHg at baseline to 23.86±15.62 at 1 week, 21.13±12.32 at 1 month, 21.61±14.11 at 3 months, 20.03±11.03 at 6 months and 19.55±10.45 at 1 year (all p<0.001). Topical medications decreased from 3.43±0.85 to 2.43±1.21 (1m), 2.07±1.20 (3m), 1.77±1.44 (6m) and 1.68±1.45 (1y) (all p<0.001). VAS pain improved from 4.49±3.48 to 0.51±1.38 (3m), 0.38±1.02 (6m) and 0.23±0.77 (1y) (all p<0.001). Qualified success was 44.9% (1m), 43.5% (3m), 49.3% (6m) and 55.1% (1y). Complications were mostly mild: chemosis 18.8%, subconjunctival hemorrhage 11.6%; hypotony 10.1%.

Conclusions

In this prospective refractory glaucoma cohort, DA-SC-CW-TSCPC achieved significant and sustained IOP reduction through 1 year, with meaningful reductions in topical therapy and pain and an acceptable safety profile.